Table 3.

Comparison of patients with and without higher-level HHV-6B reactivation

Variables	Patients who did not experience high-level HHV-6B reactivation (n = 9)	Patients who experienced higher-level HHV-6B reactivation (n = 15)	Pa
Peak HHV-6B DNA (copies/mL), median (range)	4547 (1063–14,200)	40,000 (16,500–270,800)	< 0.001
Age in years, median (range)	44 (30–64)	57 (22–70)	0.50
Age in years, ≥ 55 years	3 (33)	8 (53)	0.42
Male sex	4 (44)	9 (60)	0.68
Non-early disease status at transplantation	3 (33)	8 (53)	0.42
MAC preconditioning	7 (78)	8 (53)	0.39
TBI > 8 Gy	4 (44)	5 (33)	0.68
Acute GVHD ≥ Grade II	1 (11)	9 (60)	0.03

Data are number (%), unless otherwise indicated

MAC myeloablative conditioning, TBI total body irradiation, GVHD graft-versus-host disease, HHV-6B human herpesvirus 6B

^aFisher’s exact test